Video

Dr. Cutler on Novel Preventive Strategies Against GVHD

Corey S. Cutler, MD, MPH, FRCPC, discusses some of the novel preventive strategies against graft-versus-host disease.

Corey S. Cutler, MD, MPH, FRCPC, medical director of the Adult Stem Cell Transplantation Program; director of Clinical Research, Stem Cell Transplantation; director of the Stem Cell Transplantation Survivorship Program; and institute physician at Dana-Farber Cancer Institute; as well as an associate professor of medicine at Harvard Medical School, discusses some of the novel preventive strategies against graft-versus-host disease (GVHD).

A significant unmet need with regard to GVHD is prevention, says Cutler; however, ongoing research efforts are exploring novel preventive regimens. Specifically, investigators are developing ways to manipulate the stem cell graft, take out specific T-cell fractions, or modulate the graft to prevent GVHD, says Cutler.

Additionally, several post-transplant medical interventions are available. For example, the post-transplant cyclophosphamide regimen is growing in importance. Additionally, other immunosuppressive agents are available, such as abatacept (Orencia), which is a costimulatory blockade agent that can help prevent GVHD, concludes Cutler.

Related Videos
Aditya Bardia, MD, MPH, FASCO
Christina S. Baik, MD, MPH
Dana Zakalik, MD
David C. Fisher, MD
Kevin Kalinsky, MD, MS
Alberto Montero, MD, MBA, CPHQ
R. Lor Randall, MD, FACS
Daniel E. Haggstrom, MD
Jairam Krishnamurthy, MD, FACP
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System